Takeda tees up priority review for storied CMV drug from its $62B Shire buyout
One of the Shire drugs that Takeda spotlighted in its $62 billion takeover is getting a speedy look at the FDA.
The drug, maribavir …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
